Key result
Intramyocardial delivery of VEGF-B gene transfer prevented angiotensin II-induced diastolic dysfunction in rats, associated with increased proliferation, c-kit(+) cells, and capillary area.
Why the study?
Does intramyocardial delivery of VEGF-B gene therapy prevent left ventricular diastolic dysfunction in rats with angiotensin II-induced pressure overload?
Does intramyocardial delivery of VEGF-B gene therapy prevent left ventricular diastolic dysfunction in rats with angiotensin II-induced pressure overload?
VEGF-B gene transfer prevents angiotensin II-induced diastolic dysfunction in a rat model, highlighting a potential novel therapeutic approach for heart failure.
No takes yet. Share an insight, caveat, or question.
VEGF-B gene transfer merits further preclinical testing in diastolic dysfunction; leaves open translation to human HFpEF.
Serpi et al. (2010) studied Angiotensin II-induced diastolic dysfunction. Intramyocardial delivery of adenoviral vector expressing VEGF-B(167A) vs. LacZ control virus was evaluated on Left ventricular diastolic dysfunction. Intramyocardial delivery of VEGF-B gene transfer prevented angiotensin II-induced diastolic dysfunction in rats, associated with increased proliferation, c-kit(+) cells, and capillary area.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: